BioWorld. November 6, 2019 By Cormac Sheridan – DUBLIN – Hamlet Pharma AB is about to embark on the next phase in the clinical development…
Read More
Aktieägarna i Hamlet Pharma AB, 556568-8958, kallas härmed till årsstämma torsdagen den 21 november 2019 kl. 17.30 i Gamla Börssalen, Malmö Börshus med adress Skeppsbron…
At the end of July 2019, Hamlet Pharma announced the successful completion of the Phase I/II bladder cancer study. We now provide more detailed information…
Hamlet Pharma is proud to announce the successful outcome of the Phase I/II trial, aimed at studying the safety and efficacy of Alpha1H in patients…
The ongoing phase I/II study with 40 patients is due to complete in May/June 2019. The last study patient is expected to undergo scheduled surgery…
The phase I/II study in patients with bladder cancer addresses the safety of our drug candidate Alpha1H and measures biomarkers of efficacy. The protocol is…